Information Provided By:
Fly News Breaks for February 28, 2017
LJPC
Feb 28, 2017 | 07:22 EDT
SunTrust analyst Yatin Suneja believes that data on La Jolia's LJPC-501 was "highly favorable," supports its approval and suggests that it could become the standard of care in last-line CRH. The analyst thinks that the drug represents an opportunity of at least $500M, and he raised his price target on the name to $57 from $38 while keeping a Buy rating.
News For LJPC From the Last 2 Days
There are no results for your query LJPC